NeurAxis Expands PENFS Insurance Coverage to 18 Million Additional Lives

Key Facts

In a move reflecting the accelerating adoption of innovative medical technologies in the U.S. market, NeurAxis has announced a significant regulatory and commercial milestone. According to reports, the company secured a new medical policy coverage from a major national health insurer for its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. This expansion extends access to the company's therapies to over 18 million additional covered lives, supporting its commercialization strategy for neuromodulation treatments targeting chronic conditions.

This expansion comes as micro-cap med-tech firms strive to consolidate market share through partnerships with major healthcare providers. NeurAxis is focusing its growth on executing plans to broaden payer coverage and patient access for its proprietary technology. Per market data, this development positions the company strategically within the healthcare sector, particularly for therapies designed for patient populations aged 8 years and older.

Regarding stock performance, NRXS stood at $5.75 (close September 14, 2026), with a daily trading range between $5.31 and $6.00 on that date. Investors are watching how this insurance coverage expansion will translate into future revenue growth, while the economic calendar remains light on direct corporate catalysts for the immediate upcoming period.